Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon

Claire Rooney; Catherine Geh; Victoria Williams; Johannes M. Heuckmann; Roopika Menon; Petra Schneider; Katherine Al-Kadhimi; Michael Dymond; Neil R. Smith; Dawn Baker; Tim French; Paul D. Smith; Elizabeth A. Harrington; J. Carl Barrett; Elaine Kilgour

doi:10.1371/journal.pone.0149628

Loading metrics

Open Access

Peer-reviewed

Research Article

Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon

Claire Rooney ,

* E-mail: claire.rooney@astrazeneca.com

Affiliation AstraZeneca, Oncology Innovative Medicines, Alderley Park, Macclesfield, United Kingdom
⨯
Catherine Geh,

Affiliation AstraZeneca, Oncology Innovative Medicines, Alderley Park, Macclesfield, United Kingdom
⨯
Victoria Williams,

Affiliation AstraZeneca, Personalised Healthcare and Biomarkers Innovative Medicines, Alderley Park, Macclesfield and Melbourn, Cambridge, United Kingdom
⨯
Johannes M. Heuckmann,

Current address: NEO New Oncology AG, Cologne, Germany

Affiliation Blackfield AG, Cologne, Germany
⨯
Roopika Menon,

Current address: NEO New Oncology AG, Cologne, Germany

Affiliation Blackfield AG, Cologne, Germany
⨯
Petra Schneider,

Current address: NEO New Oncology AG, Cologne, Germany

Affiliation Blackfield AG, Cologne, Germany
⨯
Katherine Al-Kadhimi,

Affiliation AstraZeneca, Oncology Innovative Medicines, Alderley Park, Macclesfield, United Kingdom
⨯
Michael Dymond,

Affiliation AstraZeneca, Discovery Sciences Innovative Medicines, Alderley Park, Macclesfield, United Kingdom
⨯
Neil R. Smith,

Affiliation AstraZeneca, Oncology Innovative Medicines, Alderley Park, Macclesfield, United Kingdom
⨯
Dawn Baker,

Affiliation AstraZeneca, Oncology Innovative Medicines, Alderley Park, Macclesfield, United Kingdom
⨯
Tim French,

Affiliation AstraZeneca, Personalised Healthcare and Biomarkers Innovative Medicines, Alderley Park, Macclesfield and Melbourn, Cambridge, United Kingdom
⨯
Paul D. Smith,

Affiliation AstraZeneca, Oncology Innovative Medicines, Alderley Park, Macclesfield, United Kingdom
⨯
Elizabeth A. Harrington,

Affiliation AstraZeneca, Oncology Innovative Medicines, Alderley Park, Macclesfield, United Kingdom
⨯
J. Carl Barrett,

Affiliation AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts, United States of America
⨯
Elaine Kilgour

Affiliation AstraZeneca, Oncology Innovative Medicines, Alderley Park, Macclesfield, United Kingdom
⨯

Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon

Claire Rooney,
Catherine Geh,
Victoria Williams,
Johannes M. Heuckmann,
Roopika Menon,
Petra Schneider,
Katherine Al-Kadhimi,
Michael Dymond,
Neil R. Smith,
Dawn Baker

Published: February 23, 2016
https://doi.org/10.1371/journal.pone.0149628

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Gene expression
Is the Subject Area "Gene expression" applicable to this article?

Thanks for your feedback.
Signal amplification
Is the Subject Area "Signal amplification" applicable to this article?

Thanks for your feedback.
Lung and intrathoracic tumors
Is the Subject Area "Lung and intrathoracic tumors" applicable to this article?

Thanks for your feedback.
Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.
Genetic loci
Is the Subject Area "Genetic loci" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Protein expression
Is the Subject Area "Protein expression" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.